Abstract |
Treatment with interferon beta-1b (IFNB-1b) is clinically effective in multiple sclerosis patients. However, the mechanism of action is only partially understood, and validated biological response markers are lacking. We assessed IFNB-1b-induced transcriptional changes by microarray technology. Healthy male volunteers received 250 mug IFNB-1b or placebo in a double-blind, randomized controlled trial (n=5 per group). Most transcripts demonstrated peak levels after 6-12 h and returned to baseline after 48 h. We identified 227 differentially regulated genes including novel and previously described markers. This panel may become a valuable tool for development of new IFNB-1b formulations and assessment of clinical drug effects.
|
Authors | Jan Hilpert, Johanna M Beekman, Susanne Schwenke, Kristin Kowal, David Bauer, Johannes Lampe, Rupert Sandbrink, Jürgen F Heubach, Steffen Stürzebecher, Joachim Reischl |
Journal | Journal of neuroimmunology
(J Neuroimmunol)
Vol. 199
Issue 1-2
Pg. 115-25
(Aug 13 2008)
ISSN: 0165-5728 [Print] Netherlands |
PMID | 18565596
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adjuvants, Immunologic
- Immunologic Factors
- Interferon beta-1b
- Interferon-beta
|
Topics |
- Adjuvants, Immunologic
(pharmacology)
- Adult
- Double-Blind Method
- Gene Expression
(drug effects)
- Gene Expression Profiling
- Humans
- Immunologic Factors
(genetics)
- Interferon beta-1b
- Interferon-beta
(pharmacology)
- Male
- Oligonucleotide Array Sequence Analysis
- Principal Component Analysis
- Reverse Transcriptase Polymerase Chain Reaction
|